Clinical trials · New York
Acute Myeloid Leukemia, in Relapse clinical trials in New York
We’re tracking 49 recruiting acute myeloid leukemia, in relapse studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06017258RecruitingPhase 1
CAR T cell therapy for acute myeloid leukemia
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
Commack, New YorkAges 1 year+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New York, New YorkAges 18 years+ - NCT05748197RecruitingPhase 1
Study of ADCLEC.syn1 for relapsed or resistant AML
This Phase 1 study tests ADCLEC.syn1, a new treatment made from a patient’s immune cells, in adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see how safe it is and how well it may work, especially after standard treatments have not helped.
Commack, New YorkAges 18 years+ - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
New York, New YorkAges 18 years+ - NCT05732103RecruitingPhase 1/Phase 2
Testing CTX-712 for AML or high-risk MDS after prior treatment
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Rochester, New YorkAges 18 years+ - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Albany, New YorkAges 6–39 - NCT05143996RecruitingPhase 1
First study drug for relapsed AML or MDS
This Phase 1 trial tests CLN-049 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or did not respond to treatment. The goal is to find out how well the drug can work and how safe it is in people with limited options.
New York, New YorkAges 18 years+ - NCT05183035RecruitingPhase 3
Testing venetoclax for children with relapsed AML
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
New York, New YorkAges 4 weeks–21 years - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
New York, New YorkAges 12 years+ - NCT04872478RecruitingPhase 1
Early-phase drug safety and dosing study for relapsed blood cancers
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
New York, New YorkAges 12 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
New Hyde Park, New YorkAges Up to 22 years - NCT04065399RecruitingPhase 1/Phase 2
Testing revumenib for relapsed acute leukemia with certain gene changes
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
New York, New YorkAges 4 weeks+ - NCT02677064Recruiting
Study on barriers to stem cell transplant for acute leukemia
This study looks at what makes it hard for people with acute leukemia or related blood cancers to get a stem cell transplant. It aims to find ways to help more people get this treatment.
New York, New YorkAges 18–80 - NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Rochester, New YorkAges 18 years+ - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Valhalla, New YorkAges Up to 21 years - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
New York, New YorkAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
New York, New YorkAges 1–21 - NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT04811560RecruitingPhase 1/Phase 2
Study of a targeted medicine for certain relapsed leukemia
This Phase 1/2 trial tests bleximenib, a targeted medicine, for people whose acute leukemia has specific gene changes and has come back or does not respond to treatment. It may help by attacking these leukemia-specific targets when other treatment options have run out.
New York, New YorkAges 2 years+ - NCT05986240RecruitingPhase 1
Danvatirsen plus venetoclax for advanced blood cancers
This trial tests a new drug called danvatirsen, first alone and then with venetoclax, for people with advanced acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to standard treatments. The goal is to see if this combination can help shrink or control the cancer.
The Bronx, New YorkAges 18 years+ - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
New York, New YorkAges 18 years+ - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
New York, New YorkAges 18 years+ - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
New York, New YorkAges 18 years+ - NCT07155226RecruitingPhase 1/Phase 2
Study of AZD3632 for advanced blood cancers with certain gene changes
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
New York, New YorkAges 16 years+
Acute Myeloid Leukemia, in Relapse trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting acute myeloid leukemia, in relapse studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- Montefiore Medical Center · 7 studies
- Roswell Park Comprehensive Cancer Center · 6 studies
- Columbia University Irving Medical Center · 4 studies
- Albany Medical Center · 2 studies
- Memorial Sloan Kettering Nassau · 2 studies
- Memorial Sloan Kettering Westchester · 2 studies
- NYU Langone Health · 2 studies
What taking part in a acute myeloid leukemia, in relapse study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Acute Myeloid Leukemia, in Relapse trials in other states
Common questions
- Are there acute myeloid leukemia, in relapse clinical trials in New York?
- Yes. We're currently tracking 49 recruiting acute myeloid leukemia, in relapse studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute myeloid leukemia, in relapse study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute myeloid leukemia, in relapse trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute myeloid leukemia, in relapse studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.